Pernix Therapeutics (PTX -2.6%) slips this morning, despite its announcement that its Hawthorn...

|About: Pernix Therapeutics Holding... (PTX)|By:, SA News Editor

Pernix Therapeutics (PTX -2.6%) slips this morning, despite its announcement that its Hawthorn Pharmaceuticals unit has received FDA approval for Vituz, a prescription medication for coughs and colds. The company also said its Cypress Pharmaceuticals unit got final FDA approval for Mefenamic Acid Capsules, a generic version of Ponstel, for relief of mild-to-moderate pain in patients 14 years of age and older and the treatment of primary dysmenorrhea.